CVE:PDP

Pediapharm Competitors

C$0.30
+0.01 (+1.69 %)
(As of 12/18/2018)
Add
Compare
Today's Range
C$0.29
Now: C$0.30
C$0.31
50-Day Range
C$0.30
MA: C$0.30
C$0.30
52-Week Range
C$0.25
Now: C$0.30
C$0.49
Volume26,000 shs
Average Volume100,369 shs
Market CapitalizationC$66.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Pediapharm (CVE:PDP) Vs. MDNA, EMC, NEPT, IMV, FRX, and RVX

Should you be buying PDP stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Pediapharm, including Medicenna Therapeutics (MDNA), Emblem (EMC), Neptune Wellness Solutions (NEPT), IMV (IMV), Fennec Pharmaceuticals (FRX), and Resverlogix (RVX).

Pediapharm (CVE:PDP) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.

Earnings and Valuation

This table compares Pediapharm and Medicenna Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PediapharmC$11.16 million5.95C$-16,147,162.00C($0.07)-4.11
Medicenna TherapeuticsN/AN/AN/AC($0.31)-16.18

Medicenna Therapeutics has lower revenue, but higher earnings than Pediapharm. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pediapharm and Medicenna Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pediapharm0000N/A
Medicenna Therapeutics0000N/A

Profitability

This table compares Pediapharm and Medicenna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PediapharmN/AN/AN/A
Medicenna TherapeuticsN/AN/AN/A

Summary

Pediapharm beats Medicenna Therapeutics on 3 of the 3 factors compared between the two stocks.

Pediapharm (CVE:PDP) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Earnings & Valuation

This table compares Pediapharm and Emblem's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PediapharmC$11.16 million5.95$-16,147,162.00C($0.07)-4.11
Emblem$5.71 million43.02$-24,806,020.00($0.19)-9.89

Pediapharm has higher revenue and earnings than Emblem. Emblem is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Pediapharm and Emblem, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pediapharm0000N/A
Emblem0000N/A

Profitability

This table compares Pediapharm and Emblem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PediapharmN/AN/AN/A
EmblemN/AN/AN/A

Dividends

Pediapharm pays an annual dividend of C$0.14 per share and has a dividend yield of 46.7%. Emblem pays an annual dividend of $0.46 per share and has a dividend yield of 24.5%. Pediapharm pays out -191.8% of its earnings in the form of a dividend. Emblem pays out -242.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Pediapharm beats Emblem on 5 of the 7 factors compared between the two stocks.

Pediapharm (CVE:PDP) and Neptune Wellness Solutions (TSE:NEPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares Pediapharm and Neptune Wellness Solutions' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PediapharmC$11.16 million5.95C$-16,147,162.00C($0.07)-4.11
Neptune Wellness SolutionsC$52.78 million4.64C$-223,415,550.00C($1.35)-1.10

Pediapharm has higher earnings, but lower revenue than Neptune Wellness Solutions. Pediapharm is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Pediapharm and Neptune Wellness Solutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pediapharm0000N/A
Neptune Wellness Solutions00103.00

Neptune Wellness Solutions has a consensus target price of C$4.63, suggesting a potential upside of 212.50%. Given Neptune Wellness Solutions' higher possible upside, analysts clearly believe Neptune Wellness Solutions is more favorable than Pediapharm.

Profitability

This table compares Pediapharm and Neptune Wellness Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PediapharmN/AN/AN/A
Neptune Wellness SolutionsN/AN/AN/A

Summary

Neptune Wellness Solutions beats Pediapharm on 4 of the 7 factors compared between the two stocks.

Pediapharm (CVE:PDP) and IMV (TSE:IMV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares Pediapharm and IMV's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PediapharmC$11.16 million5.95C$-16,147,162.00C($0.07)-4.11
IMVC$3,000.0078,544.76C$-39,136,958.00C($0.58)-6.02

Pediapharm has higher revenue and earnings than IMV. IMV is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Pediapharm and IMV, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pediapharm0000N/A
IMV04002.00

IMV has a consensus target price of C$5.08, suggesting a potential upside of 46.07%. Given IMV's higher possible upside, analysts clearly believe IMV is more favorable than Pediapharm.

Profitability

This table compares Pediapharm and IMV's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PediapharmN/AN/AN/A
IMVN/AN/AN/A

Summary

Pediapharm beats IMV on 4 of the 6 factors compared between the two stocks.

Pediapharm (CVE:PDP) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Pediapharm and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PediapharmN/AN/AN/A
Fennec PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Pediapharm and Fennec Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pediapharm0000N/A
Fennec Pharmaceuticals00203.00

Valuation and Earnings

This table compares Pediapharm and Fennec Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PediapharmC$11.16 million5.95C$-16,147,162.00C($0.07)-4.11
Fennec PharmaceuticalsC$170,000.001,235.91C$-24,910,874.00C($0.96)-8.43

Pediapharm has higher revenue and earnings than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

Summary

Pediapharm beats Fennec Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

Resverlogix (TSE:RVX) and Pediapharm (CVE:PDP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Profitability

This table compares Resverlogix and Pediapharm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ResverlogixN/AN/AN/A
PediapharmN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Resverlogix and Pediapharm, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Resverlogix0000N/A
Pediapharm0000N/A

Valuation & Earnings

This table compares Resverlogix and Pediapharm's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/AN/AC$0.0180.00
PediapharmC$11.16 million5.95C$-16,147,162.00C($0.07)-4.11

Resverlogix has higher earnings, but lower revenue than Pediapharm. Pediapharm is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Summary

Resverlogix beats Pediapharm on 2 of the 3 factors compared between the two stocks.


Pediapharm Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MDNA
Medicenna Therapeutics
0.5$5.00+0.6%C$264.51 millionN/A-16.18
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89
NEPT
Neptune Wellness Solutions
1.2$1.48+3.4%C$244.93 millionC$52.78 million-1.10
IMV logo
IMV
IMV
1.2$3.48+1.7%C$239.70 millionC$3,000.00-6.02
FRX
Fennec Pharmaceuticals
0.5$8.08+7.1%C$210.10 millionC$170,000.00-8.43Gap Down
RVX
Resverlogix
0.7$0.88+1.1%C$205.91 millionN/A80.00Gap Down
ATE
Antibe Therapeutics
1.3$4.44+2.5%C$202.05 millionC$9.33 million-5.64
ONC
Oncolytics Biotech
1.2$3.72+0.5%C$196.30 millionN/A-6.64Analyst Report
HBP
Helix BioPharma
0.5$0.90+0.0%C$127.02 millionN/A-16.36Gap Down
IPA
ImmunoPrecise Antibodies
0.4$12.56+2.8%C$123.03 millionC$17.18 million-58.69Gap Down
ACST
Acasti Pharma Inc. (ACST.V)
0.8$0.51+7.8%C$88.79 millionC$81,000.0015.00Gap Up
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.61+1.6%C$66.76 millionC$11.64 million-11.96News Coverage
Gap Down
SBM
Sirona Biochem
0.5$0.33+6.1%C$58.80 millionC$123,870.00-25.38
PMN
ProMIS Neurosciences
0.5$0.19+5.4%C$56.60 millionC$1,787.00-9.25Gap Up
COV
Covalon Technologies
0.6$1.32+3.0%C$37.44 millionC$23.84 million-5.55News Coverage
Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.26+5.9%C$34.02 millionC$13.02 million-0.37Gap Up
IGX
IntelGenx Technologies
0.9$0.60+5.0%C$30.87 millionC$1.54 million-7.41
QPT
Quest PharmaTech
0.8$0.11+13.6%C$21.76 millionC$38,871.000.17Gap Down
CZO
Ceapro
0.7$0.74+5.4%C$21.65 millionC$16.14 million22.42Gap Up
CTX
Crescita Therapeutics
0.6$0.85+1.2%C$17.55 millionC$15.64 million425.00
KNE
Kane Biotech
0.4$0.17+3.0%C$14.12 millionC$1.34 million-4.71Gap Down
GSD
Devonian Health Group
0.5$0.26+3.8%C$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.09+11.8%C$12.70 millionN/A-3.86High Trading Volume
NSP
Naturally Splendid Enterprises
0.6$0.07+7.7%C$11.06 millionC$2.03 million-1.51
MPH
Medicure
0.7$1.61+1.9%C$10.80 millionC$12.71 million-1.04
BTI
Bioasis Technologies
0.7$0.34+13.2%C$10.16 millionC$4.12 million30.91High Trading Volume
Gap Up
HEM
Hemostemix
0.6$0.37+1.4%C$9.07 millionN/A-2.20
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.40+7.6%C$6.94 millionC$5.60 million7.31Gap Down
IOT
Innovotech
0.8$0.16+6.3%C$6.52 millionC$1.04 million80.00
BCT
BriaCell Therapeutics
0.5$4.10+2.4%C$4.48 millionN/A-1.32
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.18+0.0%C$0.00C$267.59 million50.75News Coverage
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32+5.3%C$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.